AusperBio Therapeutics has raised $120 million in series C funds to advance its oligonucleotide therapy for chronic hepatitis ...

Following Merck and Moderna’s phase 3 triumph with a Keytruda-paired personalized mRNA cancer vaccine, a similar shot from BioNTech and Genentech has ...

BioXcel Therapeutics has filed for bankruptcy and lined up a deal for T | BioXcel Therapeutics has filed for bankruptcy and ...

Roche has won an extended clearance by the FDA for its tests that can find patients eligible to use Jazz Pharmaceuticals’ ...

A new report on the health of the Massachusetts biotech scene has painted a mixed picture of how drug developers are faring ...

Roche’s Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates (ADCs) designed for the ...

Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage UCN2 ...

Osivax has licensed an influenza vaccine from GC Biopharma, positioning the biotech to build on early evidence that its ...

After announcing the “tough but necessary” decision to lay off some employees last year, Frontier Medicines is looking to the ...

Flagship Pioneering’s ProFound Therapeutics is keeping its string of high-profile partnerships going, forging a pact with the ...

While mRNA may be back in the headlines courtesy of Moderna and Merck & Co.'s phase 3 cancer vaccine success, new research ...

Many global biotech companies view China as a post-hoc commercial market, considering the country only in later stages of clinical development. | Leading biotechs are rethinking China’s role in global ...